Page last updated: 2024-08-25

rosiglitazone and Diseases, Metabolic

rosiglitazone has been researched along with Diseases, Metabolic in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	2 (50.00)	2.80

Authors

Authors	Studies
Abell, L; Ahmad, S; Apedo, A; Azzara, AV; Brigance, R; Chang, S; Chao, H; Chen, L; Cheng, D; Chu, CH; Cullen, MJ; Dabros, M; Devasthale, P; Dierks, E; Foster, K; Gao, Q; Hangeland, JJ; Harden, D; Harvey, S; Hou, X; Keim, WJ; Kempson, J; Kopcho, L; Lawrence, RM; Li, YX; Ma, Z; Mathur, A; Meng, W; Moore, F; O'Malley, K; Panemangelor, R; Pelleymounter, MA; Robl, JA; Rooney, S; Turdi, H; Wang, W; Whaley, JM; Wu, DR; Ye, XY; Zhao, G	1
Appendino, G; Calzado, MA; Eugenia Prados, M; Ferreiro-Vera, C; Garrido-Rodriguez, M; Morrugares, R; Muñoz, E; Nadal, X; Palomares, B; Ruiz-Pino, F; Sánchez-Garrido, MA; Tena-Sempere, M; Vazquez, MJ; Velasco, I	1
Araujo de Baptista, E; Baptista, T; Beaulieu, S; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E	1
Abbasi, F; Chu, JW; Cooke, JP; Lamendola, C; McLaughlin, TL; Reaven, GM; Stühlinger, MC; Tsao, PS	1

Trials

1 trial(s) available for rosiglitazone and Diseases, Metabolic

Article	Year
Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial. Pharmacopsychiatry, 2009, Volume: 42, Issue:1 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Double-Blind Method; Female; Fibrinogen; Hemoglobins; Humans; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Male; Metabolic Diseases; Middle Aged; Olanzapine; Pilot Projects; Rosiglitazone; Schizophrenia; Statistics as Topic; Thiazolidinediones	2009

Article

Year

Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial.

Pharmacopsychiatry, 2009, Volume: 42, Issue:1

Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Double-Blind Method; Female; Fibrinogen; Hemoglobins; Humans; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Male; Metabolic Diseases; Middle Aged; Olanzapine; Pilot Projects; Rosiglitazone; Schizophrenia; Statistics as Topic; Thiazolidinediones

2009

Other Studies

3 other study(ies) available for rosiglitazone and Diseases, Metabolic

Article	Year
Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders. Journal of medicinal chemistry, 2021, 10-14, Volume: 64, Issue:19 Topics: Animals; Crystallography, X-Ray; Drug Discovery; Enzyme Inhibitors; High-Throughput Screening Assays; Humans; Metabolic Diseases; N-Acetylglucosaminyltransferases; Structure-Activity Relationship	2021
Tetrahydrocannabinolic acid A (THCA-A) reduces adiposity and prevents metabolic disease caused by diet-induced obesity. Biochemical pharmacology, 2020, Volume: 171 Topics: 3T3-L1 Cells; Adipogenesis; Adiposity; Animals; Anti-Inflammatory Agents; Cells, Cultured; Diet, High-Fat; Dronabinol; Fatty Liver; HEK293 Cells; Humans; Male; Metabolic Diseases; Mice; Mice, Inbred C57BL; Obesity; PPAR gamma; Rosiglitazone	2020
Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA, 2002, Mar-20, Volume: 287, Issue:11 Topics: Adult; Aged; Arginine; Cardiovascular Diseases; Cross-Sectional Studies; Enzyme Inhibitors; Female; Humans; Hypertension; Hypoglycemic Agents; Lipoproteins; Male; Metabolic Diseases; Metabolic Syndrome; Middle Aged; Nitric Oxide Synthase; Regression Analysis; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Vasodilator Agents	2002